Jazz Pharmaceuticals plc danas je objavio da je prvi pacijent upisan u fazu 2 kliničko ispitivanje u kojem se procjenjuje sigurnost i učinkovitost JZP150, ispitivane prve u klasi male molekule za liječenje odraslih osoba s posttraumatskim stresnim poremećajem (PTSP). JZP150 je visoko selektivan inhibitor enzima amid hidrolaze masne kiseline (FAAH), dizajniran za rješavanje temeljnog uzroka PTSP-a (poremećaj izumiranja straha i njegova konsolidacija), kao i simptoma povezanih s pacijentima (tjeskoba, nesanica i noćne more).
ŠTO ISKLJUČITI IZ OVOG ČLANKA:
- JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patients’.
- Jazz Pharmaceuticals plc today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD).
- .